Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report

BACKGROUND: Renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are representative malignancies that respond well to immune checkpoint inhibitors (ICIs). Research has been conducted to identify biomarkers, such as programmed death ligand-1 (PD-L1), that would allow the response to ICI...

Descripción completa

Detalles Bibliográficos

Autores principales:	Urushibara, Masayasu, Ishizaka, Kazuhiro, Matsutani, Noriyuki, Takahashi, Mikiko, Nagata, Masakazu, Okumura, Taisuke, Matsumoto, Yuuki, Tatsuoka, Shinichiro, Nenohi, Tsunehiro, Amemiya, Takumasa, Shimizu, Yohei, Shirakawa, Takeshi, Kato, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900908/ https://www.ncbi.nlm.nih.gov/pubmed/36747242 http://dx.doi.org/10.1186/s12957-023-02920-2